In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene tests are carried out to detect gene rearrangements within in non-small cell lung cancer tumor cells; the outcome of which may guide therapies to treat non-small cell lung cancer (NSCLC). GlobalData uses proprietary data and analytics to provide a comprehensive report on the alk tests devices market, including market shares of different players within Norway. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the alk tests market in Norway was Abbott Laboratories followed by ZytoVision, F. Hoffmann-La Roche, Thermo Fisher Scientific, Qiagen, Biocare Medical, Agilent Technologies, Sysmex, Amoy Diagnostics, EntroGen, Bio-Rad Laboratories, New England Biolabs, Cancer Diagnostics, Danaher and Panagene.
This segment includes Immunohistochemistry (IHC) Tests, In Situ Hybridization (ISH) Tests, and Nucleic Acid Amplification Tests (NAATs).
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the alk tests devices market within Norway was expected to be over $0.1m in 2022.
For the latest complete market share analysis of alk tests device market in Norway, buy the report here.